This file contains detail protocols on synthetic peptide synthesis, hapten labeling of immunoreagents, Bcl-x L expression and purification, loading immunoreagents on magnetic beads, in vitro translation and fusion formation, and radiolabeled binding assays. It also contains a list of all of the DNA sequences used (Table S- 
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M Tris-HCl, pH 8.0, and buffer exchanged into 1X PBS using NAP-25 columns to remove the un-reacted NHS-fluorescein. Since the HA tag does not contain any lysine residues, the HA tag on synthetic Pep1 was not modified with a label. The concentration of the peptide and anti-HA antibody, and the average number of fluorescein labels per molecule were calculated as per manufacturer's instructions. The purified solutions contained an average of three fluorescein labels per antibody and one fluorescein label per synthetic peptide.
Biotin-labeled Bcl-x L Expression and Purification. The gene for the first 209 amino acids of
Bcl-x L (Clone HsCD00004711; Dana Farber/Harvard Cancer Center DNA Resource Core) was PCR amplified using Pfusion polymerase, and cloned into pET24a using NdeI and XhoI. An Nterminal avitag (AGGLNDIFEAQKIEWHEGG) was added for in vivo biotinylation using the BirA enzyme. 4 Bcl-x L was expressed overnight at 37 °C in BL21(DE3) cells using autoinduction media. 5 Cells were lysed using Bper (Pierce), and purified using Ni-NTA superflow resin on an FPLC (Bio-Rad), using a gradient from 10 mM to 400 mM imidazole (Buffer A: 25 mM Hepes pH 7.5, 1 M NaCl, 10 mM imidazole; Buffer B: 25 mM Hepes pH 7.5, 1 M NaCl, 400 mM imidazole). Fractions with pure Bcl-x L were combined, concentrated, and desalted into 50 mM Tris-HCl, pH 8.0. Bcl-x L was biotinylated in vitro using BirA biotin ligase (0.1 mg/mL in 50 mM Tris-HCl, pH 8.3, 10 mM ATP, 10 mM Mg(OAc) 2 , 50 µM biotin) at 30 °C for two hours. The protein was buffer exchanged into 1X PBS, frozen in liquid nitrogen, and stored at - UTR that was a deletion mutant of the Tobacco Mosaic Virus (∆TMV). 6 The C-terminal portion of the peptides were elongated with a flexible serine-glycine linker (six amino acids long) and an HA tag (Table S-1) . After gel purification using urea-PAGE, the DNA sequences were PCR amplified using Taq polymerase and in vitro transcribed into mRNA using T7 RNA polymerase. 6 After transcription, the mRNA was urea-PAGE purified and resuspended in deionized water to a final concentration of 30 µM. The mRNA was then ligated to fluorescein-F30P (phosphate-
spacer 9 (Glen Research), and P is puromycin (Glen Research); synthesized at the Keck Oligo Facility at Yale) using T4 DNA ligase. 7 The ligation was performed using a splint complementary to the 3' end of the RNA and the 5' end of the DNA-linker ( Radiolabeled Binding Assays.
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S-labeled mRNA-protein fusions translated as described above were purified using oligo-dT cellulose beads (GE Healthcare) as described elsewhere. 
